Eli Lilly director gets 4.19-share stock award
ELI LILLY & Co (LLY) director Gabrielle Sulzberger reported an acquisition of 4.1908 shares of common stock on August 17, 2026, as a grant/award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ELI LILLY & Co (LLY) director Gabrielle Sulzberger reported an acquisition of 4.1908 shares of common stock on August 17, 2026, as a grant/award. According to the director deferral plan, the value was deferred as stock units in lieu of cash compensation and will be settled in shares after her separation from service, bringing her directly held equivalent share balance to 3003.9096 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 4.1908 | $1,183.16 | $5K |
Footnotes (1)
- F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
Key Figures
Key Terms
Lilly Directors' Deferral Plan financial
stock units financial
separation from service financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did LLY director Gabrielle Sulzberger report?
At what price was the LLY stock award to Gabrielle Sulzberger valued?
How is the LLY director’s stock award settled under the Lilly Directors' Deferral Plan?
Was Gabrielle Sulzberger’s LLY transaction under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.